Jubilant Biosys gets GST order; company to appeal, no impact expected

Regulatory & Legal View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹1073.70

prior close

₹1077.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-2.3%-0.9% vs market

Pharmaceuticals peers, median of 156sector-2.0%-1.2% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.7

15m

-0.6

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-2.3-0.9-2.0-1.2

Next day

-2.6-1.3-1.3-1.3-1.3

-0.7-2.0+1.2-1.4+0.7

+1.9-1.4+3.3-1.0+2.9

+0.7-0.6+1.3-0.8+1.6

+0.9-0.2+1.2-0.6+1.5

-2.1-1.7-0.4-2.1+0.0

15d

-1.8-0.0-1.8-2.1+0.2

-0.3-0.0-0.3-1.4+1.1

-12.4-1.4-11.0-5.0-7.4

-23.2-8.7-14.5-10.8-12.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova's wholly owned subsidiary Jubilant Biosys received a GST adjudication order from the Deputy Commissioner of Commercial Taxes, Mysuru for FY 2021-22. The order demands about Rs 6.65 crore in tax, Rs 4.32 crore in interest and Rs 66.5 lakh in penalty over alleged excess or irregular availment of Input Tax Credit. The company calls the order incorrect and plans to appeal before the GST Appellate Authority.

Likely market impact

Total demand about Rs 11.63 crore. Company disputes the order, will appeal, and expects no financial or operational impact. Watch appeal outcome.